ArticleMolecular biology reports2026
Potential of Jelleine-I peptide on down-regulation of biofilm-associated genes and the biofilm formation of methicillin-resistant Staphylococcus aureus.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen with strong biofilm-forming ability, contributing to persistent infections and antibiotic resistance. This study evaluated the antibiofilm activity of Jelleine-I against MRSA and its effects on the expression of biofilm-associated genes.
methodsAntibacterial activity was assessed by the broth microdilution method and time–kill assays, while biofilm inhibition and disruption were evaluated using the microplate assay and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Resistance development was monitored over 28 days, with vancomycin as a control, and hemolytic activity was tested on human red blood cells (RBCs).
resultsJelleine-I showed a minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of 128 µM, eliminating MRSA within four hours at MIC. It inhibited biofilm formation by over 77%, disrupted mature biofilms by more than 40%, and reduced metabolic activity by over 80%. The MIC remained unchanged after 28 days, whereas vancomycin MIC increased fourfold. Jelleine-I exhibited low hemolytic activity and significantly downregulated fib (2.47-fold), icaA (2.22-fold), and icaD (1.25-fold) expression after 12 h.
conclusionsThese findings demonstrate that Jelleine-I effectively targets MRSA biofilms at both phenotypic and genetic levels, supporting its potential as a candidate for further cytotoxicity and in vivo studies.
Indexed as
Identifiers
41848960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.